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Bernard, Medical and Infectious Intensive Care Unit, Université Paris Denis Diderot, Paris, FranceAbstractEmpirical broad spectrum antimicrobial therapy prescribed in life-threatening situations should be de-escalated to mitigate the risk of
resistance emergence. Deﬁnitions of de-escalation (DE) vary among studies, thereby biasing their results. The aim of this study was to
provide a consensus deﬁnition of DE and to establish a ranking of β-lactam according to both their spectra and their ecological
consequences. Twenty-eight experts from intensive care, infectious disease and clinical microbiology were consulted using the Delphi
method (four successive questionnaires) from July to November 2013. More than 70% of similar answers to a question were necessary
to reach a consensus. According to our consensus deﬁnition, DE purpose was to reduce both the spectrum of antimicrobial therapy
and the selective pressure on microbiota. DE included switching from combination to monotherapy. A six-rank consensual
classiﬁcation of β-lactams allowing gradation of DE was established. The group was unable to differentiate ecological consequences of
molecules included in group 4, i.e. piperacillin/tazobactam, ticarcillin/clavulanic acid, fourth-generation cephalosporin and
antipseudomonal third-generation cephalosporin. Furthermore, no consensus was reached on the delay within which DE should be
performed and on whether or not the shortening of antibiotic therapy duration should be included in DE deﬁnition. This study
provides a consensual ranking of β-lactams according to their global ecological consequences that may be helpful in future studies on
DE. However, this work also underlines the difﬁculties of reaching a consensus on the relative ecological impact of each individual drug
and on the timing of DE.
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The De-escalation Group members are listed in Appendix 1.Clinical Microbiology and Infection © 2015 European Society of CIntroductionWhen prescribing an empirical antimicrobial therapy the clini-
cian is facing a major dilemma. On the one hand, there is the
risk of inappropriate initial therapy (i.e. use of antibiotics to
which the aetiological microorganism is not susceptible). OnClin Microbiol Infect 2015; 21: 649.e1–649.e10
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.03.013
649.e2 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIthe other hand is the ecological risk associated with using too
often broad-spectrum regimens [1] as is now recommended by
several authors [2]. To mitigate this risk, the de-escalation (DE)
concept, based on culture results, has been developed since
the late 1990s. In practical terms, this approach—which is
now included in the Surviving Sepsis Campaign recommenda-
tions— involves changing the empirical (and appropriate)
broad-spectrum antimicrobial(s) to a narrower-spectrum
regimen by: (a) changing the ‘pivotal’ antimicrobial agent for a
narrower-spectrum one; or (b) discontinuing an antimicrobial
combination [3]. A further strategy is to shorten the course of
the antimicrobial therapy.
Some studies have addressed the issue of DE in cohorts of
patients with speciﬁc disease, mainly ventilator-associated
pneumonia [4] or in large mixed populations, such as patients
with severe sepsis or septic shock, neutropenia [5] and in case
of empirical antimicrobial therapy [6]. However, DE rates
varied greatly among these studies and the effects on patient
outcomes and antimicrobial resistance have been conﬂicting. A
reason for these discrepancies may lie in the multiple deﬁnitions
for DE used in the literature (Table 1). Indeed, a precise
consensus deﬁnition of DE is still lacking. The concepts of broad
and narrow spectra of antibiotics are often not deﬁned or differ
among studies. Furthermore, albeit its aim is to limit the
emergence of resistance, the currently used deﬁnition of DE
surprisingly does not consider ecological effects of the antimi-
crobial agent on microbiota [7], which provides ‘colonization
resistance’ [8]. Also, none of the previous publications deﬁned
the period of time during which the DE should be performed.
The aim of this study was two-fold: ﬁrst, to reach a
consensus on the deﬁnition of DE; secondly to use this deﬁ-
nition to provide a ranking of β-lactams allowing a gradation of
DE, which might be useful for future studies evaluating the ef-
fects of DE on patient outcomes and resistance selection.MethodsAn invitation to participate in the survey was sent by mail in
June 2013 to 36 experts working in intensive care units, in-
fectious diseases and clinical microbiology selected by E.W. and
J-R.Z. according to their clinical experience, interest in the ﬁeld
as reﬂected by their international publications and on their
experience in generating guidelines.
Twenty-eight experts (listed in Appendix 1), including 11
intensive care practitioners, ten infectious disease practitioners
and seven clinical microbiologists, ﬁnally participated in four
rounds of a web-based modiﬁed Delphi method from July 2013
to November 2013 to develop both a consensual deﬁnition ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectDE and a ranking of β-lactams allowing the identiﬁcation and
the quantiﬁcation of DE events.
The literature on DE was ﬁrst reviewed using the following
key-words: ’antimicrobial therapy’ and ‘de-escalation’ to
retrieve original articles assessing the frequency and impact of
de-escalation and ﬁelds of interest were established for
exploration in the modiﬁed Delphi. After consultation of the
expert panel (EP), the scientiﬁc committee decided to deﬁne
DE speciﬁcally among β-lactams as ‘pivotal antimicrobial
agents’. Antimicrobial combinations of β-lactams with amino-
glycosides, ﬂuoroquinolones, or a glycopeptide were also
included. Infections caused by Gram-negative bacilli are the
main reason for prescribing broad-spectrum β-lactams as
pivotal antimicrobial agents, so we focused on molecules active
against these pathogens. All experts answered all rounds (ten
questions each, Table 2) by e-mail. The rounds were prepared
by the scientiﬁc committee of the study and questions were
ﬁrst tested for feasibility and clarity by four non-participant,
infectious diseases clinicians and clinical microbiologists
before distribution to the EP. Each Delphi round was delivered
by e-mail. E-mail reminders were sent until all members of the
EP had answered each round of questions. The process was
supervised by one of the investigators (E.W.). Results were
analysed after each round (by E.W. and J-R.Z.) and summary
reports describing aggregated group responses were sent to
participants to allow them to change their answers to the next-
round questionnaire. Questions exhibiting low rate of similar
response after two rounds were removed to address another
ﬁeld of interest. Similarly, all items reaching stable consensus
were also removed.
The ﬁrst two questionnaires were designed to reach a
consensus deﬁnition of DE. Then, all included β-lactams were
listed and the experts were asked to assess whether the switch
from one molecule to another was considered as: DE, no
meaningful change in therapy, or escalation. Finally, a ranking of
β-lactams according to both their spectra and their potential to
promote selective pressure was submitted to the EP validation.
The experts were asked to revise the ranking of β-lactams and
to provide written comments. More than 70% of similar an-
swers to a question were necessary to reach consensus.ResultsThe expert panel ﬁrst achieved consensus on the deﬁnition of
DE. Indeed, according to 84% of the experts, the purpose of DE
was dual: DE should reduce both the spectrum of antimicrobial
therapy and its potential to promote resistance by driving se-
lective pressure on the microbiota.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 649.e1–649.e10
TABLE 1. Current de-escalation deﬁnitions in the literature
De-escalation deﬁnition
Judgement method of the spectrum
narrowing Author (ref) Year Study design ICU patient cohort
De-escalation
rate
Narrowing spectrum of activity Predeﬁned: change from imipenem to i)
piperacillin-tazobactam or an
antipseudomonal cephalosporin in
presence of Pseudomonas aeruginosa, or
ii) a non-antipseudomonal β-lactam in
absence of P. aeruginosa.
Alvarez-Lerma [30] 2006 Prospective
observational
Nosocomial pneumonia 52%
Antimicrobial therapy ranking (ﬁve ranks)
according to spectrum against Gram-
negative organisms
Kollef [14] 2006 Prospective
observational
Ventilator-associated
pneumonia (VAP) in
severe sepsis or septic
shock
22%
According to the activity against
P. aeruginosa
Eachempati [31] 2009 Retrospective
observational
VAP in surgical patients 55%
Not speciﬁed, reviewed by a pharmacist Schlueter [32] 2010 Retrospective
observational
Health-care associated
pneumonia
76%
Not speciﬁed De Waele [6] 2010 Retrospective
observational
Prescribed empiric
meropenem
42%
Not speciﬁed Hibbard [33] 2010 Retrospective
observational
VAP 78%
Not speciﬁed Montravers [34] 2011 Prospective
observational
Suspected and conﬁrmed
infections
8%
Change from imipenem to any other
antibiotic, left to the discretion of the
physician
Kim [35] 2012 Randomised
controlled trial
Hospital-acquired
pneumonia
25%
Switching from combination to
monotherapy + narrowing
spectrum of regimen
Not speciﬁed Leone [36] 2003 Prospective
observational
Septic shock 64%
Antimicrobial therapy ranking (four
ranks) according to spectrum against
Gram-negative organisms
Giantsou [37] 2007 Prospective
observational
VAP 40%
According to the activity against
P. aeruginosa
Leone [4] 2007 Prospective
observational
VAP 42%
Not speciﬁed Shime [38] 2011 Retrospective
observational
Conﬁrmed bacteraemia 39%
Predeﬁned (change from meropenem to
any other β-lactam and from
ceftazidime, cefepime, or piperacillin-
tazobactam to amoxicillin-clavulanic
acid or any other type of penicillin) and
reviewed by a clinical pharmacist
Heenen [39] 2012 Retrospective
observational
Hospital-acquired severe
sepsis (including septic
shock)
43%
Not speciﬁed Garnacho-Montero [40] 2013 Prospective
observational
Severe sepsis and septic
shock
35%
Antimicrobial therapy ranking (ﬁve ranks)
according to spectrum against Gram-
negative organisms, as used by Kollef
et al.
Shime [41] 2013 Retrospective
observational
Conﬁrmed bacteraemia 57%
Left to the discretion of the senior
intensivist
Mokart [5] 2014 Prospective
observational
Severe sepsis in
neutropenic patients
44%
Change from imipenem to any other
antibiotic left to the discretion of the
physician
Joffe [42] 2008 Retrospective
observational
VAP 70%
Narrowing spectrum of
activity + shortening
duration/discontinuing
therapy
Predeﬁned:change from imipenem to
piperacillin-tazobactam or change from
piperacillin-tazobactam to (a)
antipseudomonal cephalosporin in
presence of P. aeruginosa (b) a non-
antipseudomonal β-lactam in absence
of P. aeruginosa.
Rello [25] 2004 Prospective
observational
VAP 38%
Switching from combination to
monotherapy + narrowing
spectrum of
activity + shortening
duration/discontinuing
therapy
According to the activity against
P. aeruginosa and predeﬁned (change
from third-generation cephalosporin to
amoxicillin)
Morel [26] 2010 Retrospective
observational
Suspected and conﬁrmed
infections
45%
Predeﬁned: change from carbapenem to
piperacillin-tazobactam and from
piperacillin-tazobactam to cefepime or
a third-generation cephalosporin
Joung [27] 2011 Retrospective
observational
Nosocomial pneumonia 32%
CMI Weiss et al. Ranking of β-lactams 649.e3Switching from combination to monotherapy was consid-
ered as DE by 92% of the experts regardless of the molecule
withdrawn or its family. Indeed, if initially included in a com-
bined regimen with a β-lactam, discontinuation of an amino-
glycoside, a ﬂuoroquinolone (ciproﬂoxacin) or a glycopeptide
(vancomycin) was considered as a DE by 85%, 100% and 96% of
the experts, respectively. Finally, none of the experts consid-
ered switching a given antibiotic from the intravenous to the
oral route as DE.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfUsing our consensual deﬁnition of DE, we achieved a six-
rank consensual classiﬁcation of β-lactams according to both
their spectrum and their resistance-promoting potential that
allowed a gradation of DE (Table 3). Molecules were listed by
increasing order of spectrum width and resistance promoting
potential so that amoxicillin was the only molecule included in
rank 1 (the less broad-spectrum and resistance-selecting
molecule) and the three carbapenems active on Pseudomonas
aeruginosa (imipenem, meropenem and doripenem) belonged toectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 649.e1–649.e10
TABLE 2. Questionnaire sent to the experts
649.e4 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMI
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 649.e1–649.e10
CMI Weiss et al. Ranking of β-lactams 649.e5rank 6 (the molecules having the broadest spectrum and the
highest selecting potential). Reaching a consensus on the
ranking of molecules eventually assigned to rank 4 (i.e. piper-
acillin/tazobactam, ticarcillin/clavulanic acid, fourth-generationClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infand antipseudomonal third-generation cephalosporins)
required four Delphi rounds. At the last round, only 71% of the
panel members ﬁnally agreed with this classiﬁcation. One-third
of the remaining experts thought that the rank of fourth-ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 649.e1–649.e10
TABLE 3. Consensual ranking of β-lactams according to both
their spectrum and their resistance-promoting potential
Rank Molecule(s)
Similar
response
rate (%)a
Consensus
reaching
round numberb
1 Amoxicillin 100 2
2 Amoxicillin + Clavulanic Acid 88 3
3 Third-generation cephalosporin
Ureido/carboxy-penicillin
81 3
4 Piperacilin + Tazobactam
Ticarcilin + Clavulanic Acid
Fourth-generation cephalosporin,
Antipseudomonal third-generation
cephalosporin
71 4
5 Ertapenem 81 3
6 Imipenem
Meropenem
Doripenem
85 2
aIndicates the proportion of the Expert Panel members that agreed with the mol-
ecules included in each rank of the classiﬁcation.
bIndicates how many rounds of the Delphi process were necessary to reach a
consensus.
649.e6 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIgeneration cephalosporins and antipseudomonal third-
generation cephalosporins should be superior to that of
piperacillin/tazobactam and ticarcillin/clavulanic acid because it
is a commonly held view that cephalosporins have a role in the
selection of extended spectrum β-lactamase (ESBL) -producing
Enterobacteriaceae [9,10] despite the results of a recent ran-
domized controlled trial challenging this driving force of ceph-
alosporins [11] One-third conversely judged that the rank of
piperacillin/tazobactam and ticarcillin/clavulanic acid was higher
because of their inhibitory effect on ‘colonization resistance’;
and the last third considered that the rank of antipseudomonal
third-generation cephalosporins was much lower because their
spectrum against Enterobacteriaceae was narrower.
We could not reach a consensus on whether or not the
shortening of antibiotic therapy duration should be included in
the deﬁnition of DE. Only 54% of the panel wished to include a
reduction of treatment duration in the consensual deﬁnition.
Among them, half thought that the reduction of selective
pressure promoting potential was more important and vice
versa. Finally, there was no agreement among panel members
about the maximum period of time during which the change in
antibiotic regimen should be performed after its initiation to
qualify for DE. Thirty-eight per cent of panel members thought
that this change should occur before day 3, and 19% before day
5, whereas 42% of the panel members thought that a change
made at any time during therapy would qualify for DE.DiscussionNo consensual deﬁnition of DE is currently available in the
literature. Hence, as shown by Table 1, various deﬁnitions or
combinations of deﬁnitions have been used in studies evaluatingClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthe safety and the effect of DE strategy, thereby confounding
their results. In most studies, narrowing the spectrum of ac-
tivity of the antibiotic regimen was all or part of the deﬁnition
[3]. However, as shown in Table 1, the methods of judgement
of the spectrum narrowing are not speciﬁed and differ greatly
across studies. Furthermore, although the global aim of DE is to
minimize the risk of selection/emergence of antimicrobial
resistance, the deﬁnitions used for spectrum narrowing sur-
prisingly do not take into account the ecological effects of an-
tibiotics on microbiota. To facilitate the conduct of future
studies on DE and their comparability, we conducted this
survey in an attempt to reach a consensual deﬁnition of DE and
to provide a ranking of β-lactams active against Gram-negative
bacilli, so allowing a gradation of DE.
According to this survey, a majority of our experts consid-
ered that, in addition to their spectrum, the global impact of
antibiotics on the microbiota and their impact on ‘colonization
resistance’ have to be considered while de-escalating antimi-
crobial therapy. Indeed, as suggested by Sullivan et al., the po-
tential ecological effects of antimicrobial agents not only
depends on their spectrum but also on their route of admin-
istration, pharmacokinetic and pharmacodynamic properties,
elimination route and in vivo inactivation [7].
Hence, the EP provides a consensual ranking of β-lactams
according to their activity spectrum and their ecological ef-
fects, using the Delphi method. This classiﬁcation might allow
both the use of homogeneous criteria for DE and the quanti-
ﬁcation of DE in future studies. To our knowledge, only three
DE studies have used an antimicrobial therapy ranking
[12–14]. Two of them provided arbitrary classiﬁcations
[13,14] and only one attempted recently to develop a nu-
merical score to rank the microbial spectrum of antibiotic
regimens [12]. Unlike our study, Madaras-Kelly et al. did not
focus on Gram-negative bacilli and only used antimicrobial
spectra to establish their ranking without considering the
ecological consequences of antimicrobial regimens [12].
Furthermore, albeit rigorous and methodologically robust,
their scoring system appears difﬁcult to implement into daily
clinical practice. Interestingly, using US national Veterans Af-
fairs susceptibility data, Madaras-Kelly et al. gave to piperacillin/
tazobactam and ticarcillin/clavulanic acid a much higher spec-
trum score than that attributed to fourth-generation cepha-
losporins and antipseudomonal third-generation
cephalosporins [12]. This difference suggests that the percep-
tion of the ecological impact of antibiotics varies among
countries and may be inﬂuenced by national epidemiological
data. Indeed, whereas the ecological consequences of a class of
antimicrobial agents are universally the same, it seems that the
perception of clinicians depends on their country’s epidemi-
ology. In the USA, vancomycin-resistant enterococci are aious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 649.e1–649.e10
CMI Weiss et al. Ranking of β-lactams 649.e7major concern [15] and anti-anaerobic antibiotics such as
piperacillin/tazobactam and ticarcillin/clavulanic acid have been
shown to favour the emergence of such pathogens [16].
Conversely, in Europe and especially in France, major emphasis
is put on the increasingly higher rates of ESBL in hospitals and
their emergence in the community [17]. Hence, our panel of
French experts judged that the resistance-promoting potential
of ESBL-inducers ceftazidime and cefepime [18], was as high as
those of piperacillin/tazobactam and ticarcillin/clavulanic acid.
However, the results of a recent randomized controlled study
evaluating the effects of selective oral decontamination and
selective digestive decontamination on antibiotic resistance
and patient outcome [11] may lead to a reconsideration of the
potential role of cephalosporin in ESBL selection. Indeed, the
authors reported a lower rate of ESBL carriage among the
selective digestive decontamination group that used a 4-day,
intravenous, third-generation cephalosporins regimen.
The ﬁve-rank classiﬁcation used by Kollef et al. included
antimicrobials active against Gram-negative pathogens and was
based on the spectrum of activity of individual drugs against
these organisms [14] Hence, carbapenems (group 5) were
considered to be the most potent drugs against Gram-negative
bacteria, followed by cefepime (group 4), ureidopenicillin/
monobactam (group 3) and quinolones (group 2). All other
drugs were grouped into rank 1 and thought to have the nar-
rowest spectrum against Gram-negative pathogens. In contrast
to Kollef et al., we intentionally focused on β-lactams because of
their status as ‘pivotal’ antimicrobial agent during sepsis and
decided not to include the whole family of quinolones in the
classiﬁcation. However, because they are frequently involved in
combination therapy, the ranking of ciproﬂoxacin as well as of
aminoglycosides and vancomycin into the DE strategy were also
considered. It is interesting to note that unlike our classiﬁca-
tion, Kollef et al. made no difference between carbapenems and
judged the spectrum of cefepime as broad as those of ure-
idopenicillin/monobactam. However, as illustrated by the
problems we faced in establishing our rank 4, judging the global
ecological effect of each antibiotic class or molecule and their
potential to induce selective pressure is difﬁcult given the
paucity of relevant information. According to the literature, the
ecological impact of antibiotics may depend on their intestinal
elimination rate and their anti-anaerobic activity [7,8]. How-
ever, most studies have been performed on animal models or in
healthy human volunteers and their results are difﬁcult to
transpose to clinical situations [7]. Indeed, although studies
performed on murine models [19] or healthy humans [7] are
useful to understand the ecological consequences of different
antibiotics, several co-interventions such as the presence of a
nasogastric tube facilitating colonization, or the administration
of proton pump inhibitors may interfere with resistance toClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infcolonization and limit the applicability of such results to clinical
settings [20,21].
De-escalation is also difﬁcult to assess because the maximum
time window during which the change in antibiotic regimen
should be performed after its initiation to qualify for DE is
undeﬁned. Indeed, similarly to our EP, Madaras-Kelly et al. were
unable to achieve a consensus regarding the optimal time-frame
to measure DE [12].
Furthermore, ratings from our EP raise questions about the
relative importance of two different measures: (a) switching to a
given class of antimicrobial because of its limited ecological
impact, and (b) reducing the global volume of antimicrobial
prescriptions, which could be a more effective strategy. The fact
that switching from combination to monotherapy was consid-
ered as DE by the EP reﬂects this view and emphasizes the need
to permanently re-assess the utility of such combination thera-
pies. Although reduction of antimicrobial volume by shortening
duration and/or discontinuing therapy has been shown to be
effective and safe [22–24], our summary of previous studies on
DE (Table 1) shows that such a strategy was only rarely included
in the deﬁnition of DE [25–27]. Interestingly, we were unable to
reach a consensus on whether or not the reduction of the
duration of antimicrobial treatment should be included in the DE
deﬁnition. Indeed, several studies demonstrated that longer
lengths of therapy select for resistant bacterial species [28,29]
but others have also clearly shown that one day of broad-
spectrum antimicrobial exposure is enough to select resistant
strains [1]. Hence several members of our EP considered that
the shortening of antimicrobial treatment duration should be
measured separately from DE. It is also noteworthy that
whereas all our EP members agreed that conversion from
intravenous to oral route could not be included in the deﬁnition
of DE, the experts from Madaras-Kelly et al. viewed oral therapy
favourably in classifying DE decisions [12].
As any Delphi process, the study suffers from some limita-
tions. The classiﬁcation of β-lactams into six levels was debated
by the EP and level 4 reached only a moderate consensus. As
discussed above, DE perception may vary among physicians
from different healthcare systems and our exclusively French-
speaking expert panel may affect the external validity of our
consensus deﬁnition. Nevertheless, our study paves the way
towards an urgently needed international consensus on DE that
will allow harmonization of practices. Furthermore, our
research could help in conducting future multicentre studies
aiming at measuring the effects of DE on patient outcomes and
on the selection of resistance.
To conclude, this study provides consensual ranking of
β-lactams according to both their activity spectrum and their
global ecological consequences that may be helpful in future
studies on DE. This work also suggests that a broadly acceptedectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 649.e1–649.e10
649.e8 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIdeﬁnition of DE is needed to help physicians in their daily clinical
decision-making when reassessing antibiotic prescriptions.Transparency declarationThe authors declare having no conﬂict of interest in relation to
this work.Appendix 1. De-escalation Study Group
MembersIntensive care practitioners:
C. Brun-Buisson: AP-HP, Hôpital Henri Mondor, Medical
Intensive Care Unit, Paris Est University Hospital, F-94010,
Creteil, France.
F. Bruneel: Hôpital André Mignot, Intensive Care Unit, F-
78150, Le Chesnay, France.
J. Chastre: AP-HP, Hôpital La Pitié Salpetrière, Medical
Intensive Care Unit, Pierre et Marie Curie University, F-75013,
Paris, France.
S. Lasocki: Hôpital d’Angers, Department of Anaesthesiology
and Critical Care, Angers University, F49000, Angers, France.
M. Leone: AP-HM, Hôpital Nord, Department of Anaes-
thesiology and Critical Care, Aix Marseille University, F-13915,
Marseille, France.
P. Montravers: AP-HP, Hôpital Bichat Claude Bernard,
Department of Anaesthesiology and Critical Care, Paris Denis
Diderot University, F-75018, Paris, France.
S. Nseir: Hôpital R. Salengro, Intensive Care Unit, Lille
University, F-59037, Lille, France.
C. Paugam-Burtz: AP-HP, Hôpital Beaujon, Department of
Anaesthesiology and Critical Care, Paris Denis Diderot Uni-
versity, F-92110, Clichy, France.
S. Pease: AP-HP, Hôpital Beaujon, Department of Anaes-
thesiology and Critical Care, Clichy, F-92110, France.
J-F. Timsit.: AP-HP, Hôpital Bichat Claude Bernard, Medical
and Infectious Intensive Care Unit, Paris Denis Diderot Uni-
versity, F-75018, Paris, France.
E. Weiss: AP-HP, Hôpital Beaujon, Department of Anaes-
thesiology and Critical Care, Paris Denis Diderot University, F-
92110, Clichy, France.
M. Wolff: AP-HP, Hôpital Bichat Claude Bernard, Medical
and Infectious Intensive Care Unit, Paris Denis Diderot Uni-
versity, F-75018, Paris, France.
Infectious disease practitioners:
S. Alfandari: Hôpital Gustave Dron, Department of Intensive
Care and Infectious Disease, F-59208, Tourcoing, France.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectB. Fantin: Hôpital Beaujon, Internal Medicine, Paris Denis
Diderot University, F-92110, Clichy, France.
B. Gachot: Institut Gustave Roussy, Department of Intensive
Care and Infectious Diseases, F94805, Paris, France.
A. Lefort: Hôpital Beaujon, Internal Medicine, Paris Denis
Diderot University, F-92110, Clichy, France.
P. Lesprit: Hôpital Foch, Laboratory of Biology, F-92151,
Suresnes, France.
J-C. Lucet: AP-HP, Hôpital Bichat Claude Bernard, Infection
Control Unit, Paris Denis Diderot University, F-75018, Paris,
France.
G. Potel: UPRES EA386 Laboratory, Clinical and Experi-
mental Therapies, Nantes University, F44000, Nantes, France.
C. Pulcini: Hôpital de Nancy, Department of Infectious
Diseases, Lorraine University, F-54000, Nancy, France.
C. Rabaud: Hôpital de Brabois, Department of Infectious
Diseases, F-54500, Vandoeuvre les Nancy, France.
P. Tattevin: Hôpital Pontchaillou, Department of Intensive
Care and Infectious Diseases, Rennes 1 University, F-35033,
Rennes, France.
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